The aim – to investigate serum levels of endothelial monocyte activating peptide II (EMAP-II) in hypertensive patients, as a marker of endothelial dysfunction, the relationship of this factor with endothelium-dependent dilatation and other risk factors of cardiovascular disease.
Material and methods. 68 hypertensive patients and 18 control subjects were examined. Serum levels of EMAP-II were determined by immune enzyme assay. Endothelium-dependent dilatation was measured by standard
D.S. Celermajer method.
Results. An increased serum level of EMAP-II was found in hypertensive patients compared to the control subjects (4.01±2.23 and 1.03±0.53 ng/ml respectively, Р<0.05). Also, the level of EMAP-II correlated with endothelium-dependent dilatation (r=–0.62, Р<0.05), serum levels of insulin, HOMA (r=0.62; r=0.72 respectively, Р<0.05), total cholesterol, HDL, LDL, triglycerides (r=0.56; r=–0.49; r=0.57; r=0.62 respectively, Р<0.05 ) HbA1c, blood glucose (r=0.66; r=0.61, respectively, Р<0.05), body mass index (r=0.25, Р<0.05). Conclusion. Serum level of EMAP-II is increased in arterial hypertension. Alteration of endothelium-dependent dilatation, hyperglycemia, dyslipidemia, insulin resistance and obesity appears to be a significant factor contributing elevation of EMAP-II. The revealed change could reflect an endothelial dysfunction under this pathological condition.